• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Thermalin looks to improve diabetes treatment with synthetic insulin

Thermalin looks to improve diabetes treatment with synthetic insulin

January 19, 2011 By MassDevice staff

Thermalin logo

Rick Berenson knows startups.

The CEO of Cleveland’s Thermalin Diabetes LLC has worked as CEO or COO for 11 different startups over the last 25 years, and Thermalin is his latest venture. But he didn’t land his spot with Thermalin through the vast professional network that he’s built up from all that time working in the startup community.

A call from his former undergraduate roommate at Harvard University, Michael Weiss, got the ball rolling with Thermalin. Weiss, the chairman of the Biochemistry Department at Case Western Reserve University School of Medicine, has developed several insulin analogs: proteins that are engineered to act like insulin in the body and offer several advantages over traditional insulins.

MedCity News logo

Weiss is the scientific mind behind Thermalin, and Berenson was brought on to develop the business. So far, the company has raised more than $3 million to support its efforts to develop and commercialize the analogs. Berenson is hoping to close another investment round between $4 million and $8 million by the end of the year that would fund clinical studies of Thermalin’s insulin analogs, which thus far have been tested only in animals.

Thermalin is aiming to take advantage of the exploding worldwide diabetes market. Worldwide insulin sales are expected to grow from $12 billion to $54 billion over the next 20 years, one of the company’s investors said last year. In 2030, there are expected to be 366 million diabetics worldwide ’ more than double the amount in 2000, according to the World Health Organization. Several drugmakers, including Eli Lilly & Co., and Sanofi-Aventis, have received FDA approval to sell insulin analogs in the U.S.

Berenson, a Boston resident, still devotes some of his time to other ventures, but about three-quarters of his work is focused on Thermalin. Berenson spoke with MedCity News about Thermalin’s plans to bring its insulin analogs to market and what advantages they might offer over what’s available now.

Q. What’s the most important thing for Thermalin to accomplish in 2011?
A. We need to select a compound to begin our first formal preclinical studies so we can get ready for clinical studies in 2012. Depending on how you count, we’ve licensed between 80 and 150 compounds from Case Western Reserve University. It’s likely that just two or three will make it to market.

Q. What makes Thermalin’s insulin analogs different from other companies’ insulin analogs that are in development or on the market?
A. The first thing to know is that diabetes patients take insulin for two purposes. First, to ensure they have at least a minimum level of insulin throughout the day, they inject a long-acting insulin once a day. Second, to have enough insulin to deal with blood sugar spikes after meals, they also often inject a meal-time insulin. The main difference between these two is their speed of action or “kinetics.”

For meal-time insulins, even existing insulin analogs, which are improved forms of regular insulin, are not fast enough in starting to work and wearing off to deal with the rapid up-and-down spike of blood sugar after a meal. For long-acting insulins, existing analogs often do not last a full day. Long-acting insulins can also have a different challenge — they have a side-effect of signaling cells to grow which some studies have suggested could, over the long term, increase cancer risk.

We have new insulin that will come on and off faster, or will last longer and have less cancer risk. It is interesting to note that currently marketed insulin analogs are going off patent in the next three or four years. Regular human insulin has been off patent for awhile. This means that the companies in the insulin market today will have to find new, superior insulin analogs or become generics companies.

Q. Do your insulin analogs offer other major advantages over insulin?
A. We also have insulins that don’t need refrigeration, which would be a boon for mail-order delivery in the U.S. and for the developing world.

Q. Talk a little about the current market for insulin analogs. Are there a lot of players? Is there a market leader?
A. There are three leading companies today in insulin: Novo Nordisk, Eli Lilly, and Sanofi-Aventis. They’ve been in the market for many years, had significant innovations, and hold significant market share. A number of other companies want to get in the market, too. Pfizer bought rights to what will soon be generic insulin analogs. Merck recently announced a deal to acquire SmartInsulin, a new insulin formulation which releases insulin in response to high glucose but which hasn’t been tested in people yet. So there are at least five players with more maybe to come.

Q. What has to happen for Thermalin to be an attractive partner to a Big Pharma company?
A. The key is going to be in our data. We need to run high-quality Phase 1 and Phase 2 trials that show that our analogs perform in a superior and advantageous way.

Filed Under: Business/Financial News, News Well Tagged With: Thermalin Diabetes LLC

In case you missed it

  • The road to a robot: Medtronic’s development process for Hugo RAS system
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
  • Zimmer Biomet appoints new chief accounting officer
  • Cook Medical makes next-gen in vitro fertilization incubator available in U.S., Canada
  • Boston Scientific co-founder Peter Nicholas is dead at 80
  • How Boston Scientific uses clinical feedback to advance innovation
  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
  • Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns
  • Abbott partners with Women as One to help more underrepresented clinicians lead trials
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • GE Healthcare to invest $50M in Pulsenmore to enter homecare segment

RSS From Medical Design & Outsourcing

  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heat wave in Texas took at least six power plants offline Friday with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS